tirzepatide and hydrochlorothiazide for Weight Loss Lisinopril / Hydrochlorothiazide Tablets |

3% of patients given placebo will lose 20% of their body weight)

TB-500 appears to influence angiogenesis (new blood vessel growth), cell migration, and tissue repair in animal models

Industry forecasts project a compound annual growth rate (CAGR) of 12.4% from 2024 to 2030 , with the market size expected to exceed $18.7 billion by 2030

Tirzepatide is not recommended in pregnancy, during breastfeeding, or in patients with severe gastrointestinal disease

As shown in Scheme 11

We believe this represents a fundamental change in shopper behavior that could reshape categories, retail strategies and growth opportunities across the industry, said Eric Savitch, SVP and group brand director at Progressive Grocer , the Path to Purchase Institute, Store Brands and Consumer Goods Technology